{"id":67397,"date":"2026-06-05T13:12:40","date_gmt":"2026-06-05T05:12:40","guid":{"rendered":"https:\/\/flcube.com\/?p=67397"},"modified":"2026-06-05T13:12:41","modified_gmt":"2026-06-05T05:12:41","slug":"everest-medicines-secures-asia-pacific-rights-to-mabworks-obexelimab-%ce%b2-in-30-9m-deal-first-in-class-cd20-antibody-for-nmosd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67397","title":{"rendered":"Everest Medicines Secures Asia-Pacific Rights to Mabworks&#8217; Obexelimab \u03b2 in $30.9M Deal \u2013 First-in-Class CD20 Antibody for NMOSD"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Everest Medicines<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>) announced a licensing agreement with fellow Chinese biopharmaceutical company <strong>Beijing Mabworks Biotech Co., Ltd.<\/strong>, acquiring <strong>clinical development and commercialization rights<\/strong> to <strong>obexelimab \u03b2<\/strong> across the <strong>Asia-Pacific region<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-transaction-details\" class=\"wp-block-heading\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Everest Medicines (licensee) \/ Beijing Mabworks Biotech (licensor)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Asia-Pacific region<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Obexelimab \u03b2 (third-generation CD20 antibody)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>RMB 23 million (USD 3.4 million)<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to RMB 186 million (USD 27.5 million) based on marketing achievements<\/td><\/tr><tr><td><strong>Additional Consideration<\/strong><\/td><td>Gross sales commission to Mabworks Bio<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to USD 30.9 million plus royalties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-regulatory-status\" class=\"wp-block-heading\">Drug Profile &amp; Regulatory Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Obexelimab \u03b2 \u2013 <strong>third-generation CD20 antibody<\/strong><\/li>\n\n\n\n<li><strong>Current Approval:<\/strong> <strong>Approved in China (February 2026)<\/strong> for <strong>neuromyelitis optica spectrum disorder (NMOSD)<\/strong><\/li>\n\n\n\n<li><strong>Global Significance:<\/strong> <strong>First-in-class<\/strong> therapy worldwide for NMOSD indication<\/li>\n\n\n\n<li><strong>Pipeline Indication:<\/strong> <strong>Primary membranous nephropathy (PMN)<\/strong> \u2013 New Drug Application currently under review in China<\/li>\n\n\n\n<li><strong>Therapeutic Potential:<\/strong> Aims to become the <strong>first specific medicine<\/strong> for PMN if approved<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-rationale\" class=\"wp-block-heading\">Market Impact &amp; Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMOSD Market Opportunity:<\/strong> Rare autoimmune disorder affecting approximately 10,000-15,000 patients in Greater China, with limited treatment options and high unmet medical need<\/li>\n\n\n\n<li><strong>PMN Market Potential:<\/strong> Primary membranous nephropathy affects an estimated 50,000-80,000 patients in China alone, representing a significantly larger commercial opportunity<\/li>\n\n\n\n<li><strong>Strategic Fit:<\/strong> Complements Everest Medicines&#8217; existing immunology and rare disease portfolio, leveraging their established commercial infrastructure across Asia-Pacific<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> First-mover status in NMOSD provides pricing power and market leadership, while potential PMN approval could establish obexelimab \u03b2 as a standard of care in nephrology<\/li>\n\n\n\n<li><strong>Regional Expertise:<\/strong> Everest&#8217;s proven track record in commercializing innovative therapies across multiple Asia-Pacific markets positions the asset for rapid uptake post-approval<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-implications\" class=\"wp-block-heading\">Financial Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Everest Medicines<\/strong><\/td><td>Modest upfront investment with significant milestone-based risk mitigation; potential revenue contribution starting 2027<\/td><\/tr><tr><td><strong>Mabworks Biotech<\/strong><\/td><td>Immediate cash infusion supporting pipeline development; ongoing revenue stream through sales commissions<\/td><\/tr><tr><td><strong>Investor Sentiment<\/strong><\/td><td>Positive reaction expected given low-risk deal structure and high-value indications<\/td><\/tr><tr><td><strong>Market Valuation<\/strong><\/td><td>Deal validates obexelimab \u03b2&#8217;s commercial potential at approximately 5-7x projected peak sales multiples<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding transaction completion, regulatory approvals, market opportunities, and financial projections for obexelimab \u03b2. Actual results may differ due to risks including regulatory decisions, market competition, and commercial execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[126,1164,1938],"class_list":["post-67397","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-everest-medicines","tag-hkg-1952","tag-mabworks-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest Medicines Secures Asia-Pacific Rights to Mabworks&#039; Obexelimab \u03b2 in $30.9M Deal \u2013 First-in-Class CD20 Antibody for NMOSD - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks Biotech Co., Ltd., acquiring clinical development and commercialization rights to obexelimab \u03b2 across the Asia-Pacific region.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67397\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Secures Asia-Pacific Rights to Mabworks&#039; Obexelimab \u03b2 in $30.9M Deal \u2013 First-in-Class CD20 Antibody for NMOSD\" \/>\n<meta property=\"og:description\" content=\"Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks Biotech Co., Ltd., acquiring clinical development and commercialization rights to obexelimab \u03b2 across the Asia-Pacific region.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67397\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T05:12:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T05:12:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67397#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67397\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Secures Asia-Pacific Rights to Mabworks&#8217; Obexelimab \u03b2 in $30.9M Deal \u2013 First-in-Class CD20 Antibody for NMOSD\",\"datePublished\":\"2026-06-05T05:12:40+00:00\",\"dateModified\":\"2026-06-05T05:12:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67397\"},\"wordCount\":370,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Everest Medicines\",\"HKG: 1952\",\"Mabworks Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67397#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67397\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67397\",\"name\":\"Everest Medicines Secures Asia-Pacific Rights to Mabworks' Obexelimab \u03b2 in $30.9M Deal \u2013 First-in-Class CD20 Antibody for NMOSD - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-05T05:12:40+00:00\",\"dateModified\":\"2026-06-05T05:12:41+00:00\",\"description\":\"Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks Biotech Co., Ltd., acquiring clinical development and commercialization rights to obexelimab \u03b2 across the Asia-Pacific region.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67397#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67397\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67397#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Secures Asia-Pacific Rights to Mabworks&#8217; Obexelimab \u03b2 in $30.9M Deal \u2013 First-in-Class CD20 Antibody for NMOSD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Secures Asia-Pacific Rights to Mabworks' Obexelimab \u03b2 in $30.9M Deal \u2013 First-in-Class CD20 Antibody for NMOSD - Insight, China&#039;s Pharmaceutical Industry","description":"Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks Biotech Co., Ltd., acquiring clinical development and commercialization rights to obexelimab \u03b2 across the Asia-Pacific region.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67397","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Secures Asia-Pacific Rights to Mabworks' Obexelimab \u03b2 in $30.9M Deal \u2013 First-in-Class CD20 Antibody for NMOSD","og_description":"Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks Biotech Co., Ltd., acquiring clinical development and commercialization rights to obexelimab \u03b2 across the Asia-Pacific region.","og_url":"https:\/\/flcube.com\/?p=67397","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-05T05:12:40+00:00","article_modified_time":"2026-06-05T05:12:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67397#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67397"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Secures Asia-Pacific Rights to Mabworks&#8217; Obexelimab \u03b2 in $30.9M Deal \u2013 First-in-Class CD20 Antibody for NMOSD","datePublished":"2026-06-05T05:12:40+00:00","dateModified":"2026-06-05T05:12:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67397"},"wordCount":370,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Everest Medicines","HKG: 1952","Mabworks Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67397#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67397","url":"https:\/\/flcube.com\/?p=67397","name":"Everest Medicines Secures Asia-Pacific Rights to Mabworks' Obexelimab \u03b2 in $30.9M Deal \u2013 First-in-Class CD20 Antibody for NMOSD - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-05T05:12:40+00:00","dateModified":"2026-06-05T05:12:41+00:00","description":"Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks Biotech Co., Ltd., acquiring clinical development and commercialization rights to obexelimab \u03b2 across the Asia-Pacific region.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67397#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67397"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67397#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Secures Asia-Pacific Rights to Mabworks&#8217; Obexelimab \u03b2 in $30.9M Deal \u2013 First-in-Class CD20 Antibody for NMOSD"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67397"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67397\/revisions"}],"predecessor-version":[{"id":67399,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67397\/revisions\/67399"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}